rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Julian Adams

Director

Company insider

Files Form 4 as: Director, Elicio Therapeutics; Chief Executive Officer, Gamida Cell; Director, Palvella Therapeutics; President of R&D, Infinity Pharmaceuticals.

Every Form 4 they filed

In numbers

Trades disclosed
43
Buys
0
Sells
0
Bought
$0
Sold
$0
Companies
4
Companies where not an officer
2
First trade
12 Sep 2006
Last trade
31 Aug 2026
Last filed
2 Sep 2026

Companies traded

Where they are an officer
Gamida CellDirector, Officer · last 31 Jan 20240 buys · 0 sells
Infinity PharmaceuticalsOfficer · last 31 Oct 20160 buys · 0 sells
Everywhere else they filed: board seats, 10% stakes, other companies
ELTX Elicio TherapeuticsDirector · Biotechnology · last 31 Aug 20260 buys · 0 sells
PVLA Palvella TherapeuticsDirector · Biotechnology · last 25 Jan 20180 buys · 0 sells

Activity over time

Not enough dated trades to draw.

Every trade

TradedCompanyWhatAmount
31 Aug 2026filed 2 Sep 2026ELTX Elicio Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—21,750 at $0.00filing
31 Aug 2026filed 2 Sep 2026ELTX Elicio Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—21,750 at $0.00filing
19 May 2025filed 20 May 2025ELTX Elicio Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—7,900 at $0.00filing
21 Nov 2024filed 25 Nov 2024ELTX Elicio Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—4,100 at $0.00filing
31 Jan 2024filed 2 Feb 2024Gamida CellSEC FORM 4 Code A—200,000 at $0.00filing
28 Dec 2023filed 29 Dec 2023ELTX Elicio Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—4,100 at $0.00filing
19 Oct 2023filed 20 Oct 2023Gamida Celloption or derivativeSEC FORM 4 Code A—56,600 at $0.00filing
19 Oct 2023filed 20 Oct 2023Gamida CellSEC FORM 4 Code A—28,300 at $0.00filing
8 Feb 2023filed 10 Feb 2023Gamida Celloption or derivativeSEC FORM 4 Code A—56,600 at $0.00filing
8 Feb 2023filed 10 Feb 2023Gamida CellSEC FORM 4 Code A—28,300 at $0.00filing
18 Nov 2022filed 22 Nov 2022Gamida Celloption or derivativeSEC FORM 4 Code A—9,500 at $0.00filing
18 Nov 2022filed 22 Nov 2022Gamida CellSEC FORM 4 Code A—2,000 at $0.00filing
27 Jul 2022filed 10 Aug 2022Gamida Celloption or derivativeSEC FORM 4 Code A—291,100 at $0.00filing
27 Jul 2022filed 10 Aug 2022Gamida CellSEC FORM 4 Code A—48,500 at $0.00filing
27 Jul 2022filed 10 Aug 2022Gamida CellSEC FORM 4 Code A—68,800 at $0.00filing
25 Jan 2018filed 29 Jan 2018PVLA Palvella Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—20,000 at $0.00filing
25 Jan 2017filed 30 Jan 2017PVLA Palvella Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—20,000 at $0.00filing
31 Oct 2016filed 2 Nov 2016Infinity PharmaceuticalsSEC FORM 4 Code A—59,150 at $0.00filing
25 Jul 2016filed 26 Jul 2016PVLA Palvella Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—30,000 at $0.00filing
6 Jan 2016filed 8 Jan 2016Infinity Pharmaceuticalsoption or derivativeSEC FORM 4 Code A—80,000 at $0.00filing

News

No headline names them, or the companies they trade most, lately.

Sectors

No trade we could place in a sector.

Related people

Nobody else traded the same names lately.